Thelansis

 Breast cancer, particularly hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes, stands as the predominant malignancy affecting young women globally, constituting roughly 30% of new cancer diagnoses and accounting for 25% of cancer-related deaths. The prognosis and clinical trajectory of metastatic breast cancer patients are highly variable, influenced by diverse factors, including patient characteristics such as age and existing health conditions, as well as tumor attributes like hormone receptor status, tumor grade, and site of metastasis. Although the median survival period for metastatic breast cancer is typically 2-4 years, specific subgroups may experience extended survival, particularly those with less aggressive or localized metastatic disease. Initial diagnosis reveals metastatic spread in about 6%-10% of cases. Despite advancements in treatment strategies for metastatic breast cancer, the impact on overall survival remains modest. Presently, metastatic bre...

  Breast Cancer (HR+VE/ HER2 -VE) is the most common malignancy in young women worldwide, accounting for an estimated 30% of new cancer diagnoses and 25% of cancer deaths. Patients with metastatic breast cancer are heterogeneous patients whose prognoses and clinical courses can vary depending on host factors, such as comorbidity and age, and on tumor factors, such as hormone-receptor status, grade, and anatomical site of disease. Although the median survival time for patients with metastatic breast cancer is 2-4 years, subsets of patients with either indolent or limited metastatic disease may have prolonged survival times. Approximately 6%-10% of patients will present with metastatic disease at diagnosis. Despite our newer strategies and treatments for MBC, their impact on survival is small. Currently, MBC is largely considered incurable, and the treatment goals are generally palliative. Nevertheless, with the development of newer agents, prolongation of survival has become a goal ...